Reuters logo
4 months ago
BRIEF-Geron Corp and Janssen Research & Development LLC has completed second internal data reviews of Imerge and Imbark
April 10, 2017 / 11:59 AM / 4 months ago

BRIEF-Geron Corp and Janssen Research & Development LLC has completed second internal data reviews of Imerge and Imbark

April 10 (Reuters) - Geron Corp

* Geron Corp - Janssen Research & Development, LLC has completed second internal data reviews of Imerge and Imbark

* Geron Corp - For imerge, benefit/risk profile of Imetelstat in treated patients supports continued development in lower risk myelodysplastic syndromes

* Geron-For Imbark, current results suggest clinical benefit, potential os benefit associated with Imetelstat treatment in relapsed or refractory myelofibrosis

* Geron Corp - For Imerge, a data package and proposed trial design refinements are planned to be provided to FDA

* Geron Corp - For Imbark, trial will continue unchanged to evaluate maturing efficacy and safety data, including an assessment of overall survival

* Geron Corp - If part 2 of imerge is initiated, Geron expects this phase 3 stage of Imerge to be opened for patient enrollment in Q4 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below